VJHemOnc – The video journal of hematological oncology

The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

Assessing high-risk AML

Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, explores how high-risk acute myeloid leukemia (AML) can be identified…

VJHemOnc – The video journal of hematological oncology

The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

Enasidenib Plus Best Supportive Care Misses OS End Point in Relapsed/Refractory IDH2+ AML

Enasidenib in combination with best supportive care failed to significantly improve overall survival in patients with relapsed/refractory acute myeloid leukemia whose tumors harbor an IDH2 mutation.

JNCCN 360 – CML – Link Between Cognitive Impairment and Outcomes in Older Recipients of Allogeneic HCT?

By: Lauren Harrison, MS Posted: Friday, August 21, 2020 Cognitive impairment appears to be associated with inferior overall survival by increasing the nonrelapse mortality in patients who received allogeneic hematopoietic stem cell transplantation (alloHCT) for treatment of CML. Andrew Artz, MD, MS, of the…

Texas MPN Workshop 2020 | VJHemOnc

Skip to contentAboutEditorial BoardExpert indexCookie PolicyTerms of UsePrivacy PolicyEditorial policySign upContactNewsletters Visit Home (current) Diseases CLL Multiple Myeloma Lymphoma MDS Amyloidosis MPNs AML CML ALL View all Diseases Topics Transplantation Measurable Residual Disease Real-World Data CAR-T & Cellular Therapy Immuno-Oncology Diagnosis…

Registration – Virtual – Data Processing Consent

Why we ask for your consentWe are committed to protecting the privacy of all personal data or photos taken during the event. The following statements describe what we are doing with your data and how long we store it so that you are fully informed prior to submitting your personal data and photos taken during the event. Your active participation in this process is your explicit consent to the…

Update on momelotinib for myelofibrosis

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, updates us on the clinical use of momelotinib, a…

Pacritinib activity against myelofibrosis

John Mascarenhas, MD, of of the Icahn School of Medicine at Mount Sinai, New York, NY, discusses pacritinib, a JAK2…

Ruxolitinib in 2020 and beyond

Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the use and impact of ruxolitinib for treating patients with myeloproliferative neoplasms…